Clinical benefit was observed upon treatment with trastuzumab and the cancer vaccine nelipepimut-S (NPS) after completion of standard treatment in the TNBC subgroup of a phase II trial for high-risk HER2-low breast cancer [91, 92]. This evidence concerns the gene ERBB2 and breast carcinoma.